Saroglitazar, a PPARα/γ dual agonist, significantly reduced alanine aminotransferase levels, insulin resistance, dyslipidemia, hepatic steatosis, and fibrosis markers in MASLD patients during phase II trials (4 mg dose) [252]. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.